Concord Biotech Limited (CONCORDBIO) - Total Liabilities
Based on the latest financial reports, Concord Biotech Limited (CONCORDBIO) has total liabilities worth Rs1.96 Billion INR (≈ $21.24 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Concord Biotech Limited - Total Liabilities Trend (2020–2025)
This chart illustrates how Concord Biotech Limited's total liabilities have evolved over time, based on quarterly financial data. See Concord Biotech Limited (CONCORDBIO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Concord Biotech Limited Competitors by Total Liabilities
The table below lists competitors of Concord Biotech Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
USA | $23.43 Million |
|
Arcelik AS
IS:ARCLK
|
Turkey | TL483.45 Billion |
|
Jiangsu Dagang Co Ltd
SHE:002077
|
China | CN¥725.39 Million |
|
Fila Holdings Corp
KO:081660
|
Korea | ₩2.75 Trillion |
|
Guizhou Panjiang Refined Coal Co Ltd
SHG:600395
|
China | CN¥34.93 Billion |
|
NRW Holdings Limited
F:3NR
|
Germany | €1.09 Billion |
|
Savaria Corporation
TO:SIS
|
Canada | CA$458.12 Million |
|
Jilin Chemical Fibre Co Ltd
SHE:000420
|
China | CN¥9.15 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Concord Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Concord Biotech Limited.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Concord Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Concord Biotech Limited (2020–2025)
The table below shows the annual total liabilities of Concord Biotech Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs2.22 Billion ≈ $23.96 Million |
+27.27% |
| 2024-03-31 | Rs1.74 Billion ≈ $18.82 Million |
-22.29% |
| 2023-03-31 | Rs2.24 Billion ≈ $24.22 Million |
+6.88% |
| 2022-03-31 | Rs2.10 Billion ≈ $22.66 Million |
+14.41% |
| 2021-03-31 | Rs1.83 Billion ≈ $19.81 Million |
+7.57% |
| 2020-03-31 | Rs1.70 Billion ≈ $18.42 Million |
-- |
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenola… Read more